Teresa M. L. Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Teresa M. L. Lee has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Antonios Kourliouros
Department of Cardiothoracic Surgery, Oxford Heart Centre, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK
1 shared publication - Brijesh V. Patel
Division of Anaesthetics, Pain Medicine, and Intensive Care, Department of Surgery and Cancer, Imperial College, London, United Kingdom
1 shared publication - Kieran P. O'DEa
Division of Anaesthetics, Pain Medicine, and Intensive Care, Department of Surgery & Cancer, Imperial College London, London, United Kingdom
1 shared publication - Laura Claire Price
Royal Brompton Hospital, London, United Kingdom
1 shared publication - Paolo Bianchi
Adult Intensive Care Unit Royal Brompton Hospital, Royal Brompton & Harefield Hospitals (part of Guy's and St Thomas's Foundation Trust) London UK
1 shared publication - Stephane Ledot
Department of Anesthesiology, Critical Care and Pain Medicine, Hadassah Medical Organization and Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel
1 shared publication
Latest Publications
- Open Access
- 15 July 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 208 (2) , 125-127
CLUSTERINg Circulating Histones in Sepsis
- 15 July 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 208 (2) , 125-127
Open AccessCLUSTERINg Circulating Histones in Sepsis
- 20 October 2022
- Published by Wiley in Artificial Organs
- Vol. 47 (3) , 595-603
Percutaneous oxygenated right ventricular assist device for pulmonary embolism: A case series
Acute right ventricular (RV) failure following massive pulmonary embolism (PE) can have significant hemodynamic consequences and is the mode of death. Temporary mechanical circulatory support can provide tissue perfusion required while thrombectomy or lysis‐aimed therapies act to relieve the thrombotic obstruction. Veno‐arterial extracorporeal membrane oxygenation (V‐A ECMO) has conventionally been the first line MCS. A more selective approach to RV support has been advocated in the form of an extracorporeal right ventricular assist device (RVAD) as it mitigates some of the shortcomings of V‐A ECMO. We present the first case series of four patients who received fully percutaneous RVAD, with an integrated oxygenator forming an Oxy‐RVAD, for selective right heart support following massive PE, including the application of single‐access dual‐lumen right atrium to pulmonary artery cannula. All patients achieved RV recovery and were successfully weaned from oxy‐RVAD support within 5–10 days demonstrating the feasibility of selective percutaneous right heart support in managing these challenging patients.
- 20 October 2022
- Published by Wiley in Artificial Organs
- Vol. 47 (3) , 595-603
Percutaneous oxygenated right ventricular assist device for pulmonary embolism: A case series
Acute right ventricular (RV) failure following massive pulmonary embolism (PE) can have significant hemodynamic consequences and is the mode of death. Temporary mechanical circulatory support can provide tissue perfusion required while thrombectomy or lysis‐aimed therapies act to relieve the thrombotic obstruction. Veno‐arterial extracorporeal membrane oxygenation (V‐A ECMO) has conventionally been the first line MCS. A more selective approach to RV support has been advocated in the form of an extracorporeal right ventricular assist device (RVAD) as it mitigates some of the shortcomings of V‐A ECMO. We present the first case series of four patients who received fully percutaneous RVAD, with an integrated oxygenator forming an Oxy‐RVAD, for selective right heart support following massive PE, including the application of single‐access dual‐lumen right atrium to pulmonary artery cannula. All patients achieved RV recovery and were successfully weaned from oxy‐RVAD support within 5–10 days demonstrating the feasibility of selective percutaneous right heart support in managing these challenging patients.